Roche and Spark Therapeutics have made public the extension of the deadline to conclude the Swiss biopharma’s $4.8 billion acquisition of Spark by three months, to April 30, 2020. The announcement comes shortly after the U.S. Federal Trade Commission initiated an unusual second request of the transaction to evaluate antitrust implications. In an email to Spark employees, Roche CEO Severin Schwan reiterated the group’s intent to complete the acquisition. Roche-Spark is one of two recent biopharma transactions, the other being the BMS acquisition of Celgene, that has been the subject of FTC scrutiny. Learn More